Mohammad Noshi

Akanocure Pharmaceuticals, Inc.

$2,174,995

Attributed

$2,174,995

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1M · FY2018–24

$1M$750K$500K$250K$0

'18

'19

'20

'21

'22

'23

'24

Funding mix

By agency

NSF$2,174,995 · 3

By mechanism

—$2,174,995 · 3

Top collaborators

No co-investigators on record.

Grant awards (3)

SBIR Phase II: A Novel Host-Directed Broad-Spectrum Antiviral and Efficient Immunomodulatory Agent Against Coronaviruses: Lead Optimization Studies$1,000,000

· FY2024 · TIP · contact PI

SBIR Phase II: Multiplex Expansion of the Chiral Carbon Catalog Platform towards Stereo-enriched Non-propionate Chemical Classes and Industrial Applications$949,999

· FY2020 · TIP · contact PI

SBIR Phase I: Novel Stereo-enriched Libraries as Commercial Complex Building Blocks for Facile Development of Biologically Active Compounds on Large Scale$224,996

· FY2018 · TIP · contact PI